These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Daptomycin in bone and joint infections: a review of the literature. Rice DA; Mendez-Vigo L Arch Orthop Trauma Surg; 2009 Nov; 129(11):1495-504. PubMed ID: 18989686 [TBL] [Abstract][Full Text] [Related]
4. Daptomycin: a review 4 years after first approval. Sauermann R; Rothenburger M; Graninger W; Joukhadar C Pharmacology; 2008; 81(2):79-91. PubMed ID: 17940348 [TBL] [Abstract][Full Text] [Related]
5. Newer treatment options for skin and soft tissue infections. Raghavan M; Linden PK Drugs; 2004; 64(15):1621-42. PubMed ID: 15257625 [TBL] [Abstract][Full Text] [Related]
6. Linezolid for the treatment of resistant gram-positive cocci. Bain KT; Wittbrodt ET Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064 [TBL] [Abstract][Full Text] [Related]
16. Daptomycin antimicrobial activity tested against methicillin-resistant staphylococci and vancomycin-resistant enterococci isolated in European medical centers (2005). Sader HS; Watters AA; Fritsche TR; Jones RN BMC Infect Dis; 2007 Apr; 7():29. PubMed ID: 17442104 [TBL] [Abstract][Full Text] [Related]
17. Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections. Eisenstein BI Expert Opin Investig Drugs; 2004 Sep; 13(9):1159-69. PubMed ID: 15330747 [TBL] [Abstract][Full Text] [Related]
18. Antimicrobial management of complicated skin and skin structure infections in the era of emerging resistance. Lee SY; Kuti JL; Nicolau DP Surg Infect (Larchmt); 2005; 6(3):283-95. PubMed ID: 16201938 [TBL] [Abstract][Full Text] [Related]